[go: up one dir, main page]

ES8705459A1 - Procedimiento para la obtencion de nuevos compuestos este- roides - Google Patents

Procedimiento para la obtencion de nuevos compuestos este- roides

Info

Publication number
ES8705459A1
ES8705459A1 ES544768A ES544768A ES8705459A1 ES 8705459 A1 ES8705459 A1 ES 8705459A1 ES 544768 A ES544768 A ES 544768A ES 544768 A ES544768 A ES 544768A ES 8705459 A1 ES8705459 A1 ES 8705459A1
Authority
ES
Spain
Prior art keywords
spiroxanes
analogues
preparation
pharmaceutical compositions
open ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES544768A
Other languages
English (en)
Other versions
ES544768A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of ES544768A0 publication Critical patent/ES544768A0/es
Publication of ES8705459A1 publication Critical patent/ES8705459A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/001—Lactones
    • C07J21/003—Lactones at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/007—3 membered carbocyclic rings in position 6-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

METODO DE OBTENER NUEVOS COMPUESTOS ESTEROIDES. CONSISTE EN TRATAR UN COMPUESTO DE FORMULA (II) CON UN AGENTE DE OXIDACION, EN PRESENCIA DE UN DISOLVENTE ORGANICO INERTE, A PRESION NORMAL Y A UNA TEMPERATURA ENTRE C10 Y 50JC, PARA OBTENER NUEVOS COMPUESTOS ESTEROIDES DE FORMULA (I) DONDE A-A- SIGNIFICA EL GRUPO -CH2-CH2- O CHFCH-; R1 ES H; R2 ES UN ALCOXI INFERIOR-CARBONILO A-ORIENTADO Y OTROS; X ES DOS ATOMOS DE HIDROGENO U OXO; E Y1 E Y2 JUNTOS FORMAN EL PUENTE OXIGENO -O- Y OTROS. TIENEN APLICACIONES FARMACEUTICAS COMO DIURETICOS.
ES544768A 1983-04-13 1985-07-01 Procedimiento para la obtencion de nuevos compuestos este- roides Expired ES8705459A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH198183 1983-04-13

Publications (2)

Publication Number Publication Date
ES544768A0 ES544768A0 (es) 1987-05-01
ES8705459A1 true ES8705459A1 (es) 1987-05-01

Family

ID=4223123

Family Applications (4)

Application Number Title Priority Date Filing Date
ES531517A Granted ES531517A0 (es) 1983-04-13 1984-04-11 Procedimiento para la obtencion de nuevos compuestos esteroides
ES544769A Expired ES8705460A1 (es) 1983-04-13 1985-07-01 Procedimiento para la obtencion de nuevos compuestos este- roides
ES544770A Expired ES8705461A1 (es) 1983-04-13 1985-07-01 Procedimiento para la obtencion de nuevos compuestos este- roides
ES544768A Expired ES8705459A1 (es) 1983-04-13 1985-07-01 Procedimiento para la obtencion de nuevos compuestos este- roides

Family Applications Before (3)

Application Number Title Priority Date Filing Date
ES531517A Granted ES531517A0 (es) 1983-04-13 1984-04-11 Procedimiento para la obtencion de nuevos compuestos esteroides
ES544769A Expired ES8705460A1 (es) 1983-04-13 1985-07-01 Procedimiento para la obtencion de nuevos compuestos este- roides
ES544770A Expired ES8705461A1 (es) 1983-04-13 1985-07-01 Procedimiento para la obtencion de nuevos compuestos este- roides

Country Status (23)

Country Link
US (1) US4559332A (es)
EP (1) EP0122232B1 (es)
JP (1) JPS59231100A (es)
AR (4) AR241918A1 (es)
AT (1) ATE39256T1 (es)
AU (1) AU565017B2 (es)
CA (1) CA1220781A (es)
DD (2) DD251144A5 (es)
DE (2) DE3475622D1 (es)
DK (1) DK163988C (es)
ES (4) ES531517A0 (es)
FI (1) FI77669C (es)
GR (1) GR81834B (es)
HU (1) HU191406B (es)
IE (1) IE57541B1 (es)
IL (1) IL71504A (es)
LU (1) LU91072I2 (es)
NL (1) NL300144I1 (es)
NO (1) NO159800C (es)
NZ (1) NZ207826A (es)
PH (1) PH19997A (es)
PT (1) PT78413B (es)
ZA (1) ZA842710B (es)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670551A (en) * 1984-06-21 1987-06-02 Ciba-Geigy Corporation Epoxy steroids
WO1992012991A1 (fr) * 1991-01-29 1992-08-06 Shionogi Seiyaku Kabushiki Kaisha Derive de triterpene
US6150347A (en) * 1992-04-21 2000-11-21 The Curators Of The University Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
US6245755B1 (en) 1992-04-21 2001-06-12 Curators Of The Unversity Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
JPH05329410A (ja) * 1992-05-29 1993-12-14 Sekisui Plastics Co Ltd マスキング材
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6262277B1 (en) * 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
CZ297975B6 (cs) * 1995-06-07 2007-05-09 G. D. Searle & Co. Farmaceutická kombinace antagonisty receptoru proangiotensin II a epoxymexrenonu pro lécení kardiovaskulárních poruch
AU6039296A (en) * 1995-06-07 1996-12-30 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldoste rone antagonist
AU747959B2 (en) * 1995-12-11 2002-05-30 G.D. Searle & Co. Processes and intermediates for the preparation of 9, 11-epoxy steroids
US20050159594A1 (en) * 1995-12-11 2005-07-21 Pharmacia Corporation Eplerenone crystal form exhibiting enhanced dissolution rate
US20020045746A1 (en) * 1995-12-11 2002-04-18 Barton Kathleen P. Eplerenone crystalline form
US20020038021A1 (en) * 1995-12-11 2002-03-28 Barton Kathleen P. Eplerenone crystalline form exhibiting enhanced dissolution rate
WO1997021720A2 (en) * 1995-12-11 1997-06-19 G.D. Searle And Co. Processes for preparation of 7 alpha-carboxyl 9,11-epoxy steroids and intermediates useful therein and a general process for the epoxidation of olifinic double bonds
US20050267302A1 (en) * 1995-12-11 2005-12-01 G.D. Searle & Co. Eplerenone crystalline form exhibiting enhanced dissolution rate
EP1170299A3 (en) * 1995-12-11 2004-11-10 G.D. Searle & Co. Intermediates useful in the preparation of 9,11-epoxy steroids and methods for their production
US6887991B1 (en) * 1996-12-11 2005-05-03 G. D. Searle & Company Processes for preparation of 9, 11-epoxy steroids and intermediates useful therein
PL189459B1 (pl) 1996-12-11 2005-08-31 Searle & Co Sposób wytwarzania delta-4,5-steroidu podstawionego 3-keto-7 alfa-alkoksykarbonylem oraz związki pośrednie i sposoby ich wytwarzania
EP1148061B1 (en) * 1996-12-11 2007-10-17 G.D. Searle LLC. Epoxidation process
ZA9711038B (en) * 1996-12-11 1999-01-25 Searle & Co Spr process for preparation of 9,11-Epoxy steroids and intermediates useful therein
EP1000547A4 (en) * 1998-05-29 2004-05-06 Kyowa Hakko Kogyo Kk METHOD FOR PRODUCING LIQUID SPICES WITH THE TASTE OF VEGETABLES MARINATED IN SALTED RICE BRANCH
EP1126880A2 (en) * 1998-11-06 2001-08-29 G.D. SEARLE & CO. Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
PT1140184E (pt) 1998-12-23 2003-10-31 Searle Llc Combinacoes de inibidores de proteina de transferencia de ester de colesterilo com derivados de acido nicotinico para indicacoes cardiovasculares
KR20010102964A (ko) * 1998-12-23 2001-11-17 윌리암스 로저 에이 심장혈관 징후를 위한 회장 담즙산 수송 억제인자 및피브린산 유도체의 조합물
PL348503A1 (en) * 1998-12-23 2002-05-20 Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
CA2356422C (en) * 1998-12-23 2008-09-16 G.D. Searle Llc Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
DE69908644T2 (de) 1998-12-23 2004-05-13 G.D. Searle Llc, Chicago Kombnationen von cholesteryl ester transfer protein inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen
US6462091B1 (en) 1998-12-23 2002-10-08 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
EA200100704A1 (ru) * 1998-12-23 2002-02-28 Джи.Ди.Сирл Ллс Комбинация для применения по сердечно-сосудистым показаниям
CN1338945A (zh) * 1998-12-23 2002-03-06 G·D·瑟尔有限公司 适用于心血管疾病的回肠胆汁酸转运抑制剂和胆汁酸螯合剂组合
US20030203884A1 (en) * 1999-11-09 2003-10-30 Pharmacia Corporation Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
US20030096798A1 (en) * 1999-11-09 2003-05-22 Williams Gordon H. Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
EP1527782A1 (en) * 1999-12-08 2005-05-04 Pharmacia Corporation Nanoparticulate eplerenone compositions
US20030083493A1 (en) * 1999-12-08 2003-05-01 Barton Kathleen P. Eplerenone drug substance having high phase purity
JP4219105B2 (ja) * 1999-12-08 2009-02-04 ファルマシア コーポレーション エプレレノン結晶形
ES2240209T3 (es) * 1999-12-08 2005-10-16 Pharmacia Corporation Composiciones de eplerenona nanoparticulada.
EP1505072A3 (en) * 1999-12-08 2006-06-21 Pharmacia Corporation Eplerenone crystalline form exhiniting enhanced dissolution rate
NZ513961A (en) * 1999-12-08 2004-02-27 Pharmacia Corp Eplerenone crystalline form exhibiting enhanced dissolution rate
WO2001068096A2 (en) * 2000-03-10 2001-09-20 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
HK1052183A1 (zh) 2000-03-10 2003-09-05 Pharmacia Corporation 制造tetrahydrobenzothiepines的方法
AU2001261434A1 (en) * 2000-05-11 2001-11-26 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
AU1604001A (en) * 2000-06-13 2001-12-24 Pharmacia Corp Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
WO2002009760A2 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
DK1313485T3 (da) * 2000-08-28 2005-12-27 Pharmacia Corp Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion
CN1531590A (zh) * 2000-10-30 2004-09-22 赭曲霉11α-羟化酶和氧化还原酶
EP1343530B1 (en) * 2000-11-09 2007-08-08 AstraZeneca AB Oral pharmaceutical composition containing a block copolymer
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20040077625A1 (en) * 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
JP2005518347A (ja) * 2001-11-02 2005-06-23 ジー．ディー． サール エルエルシー 頂端ナトリウム共依存性胆汁酸輸送（ａｓｂｔ）およびタウロコール酸塩取り込みの阻害剤としての新規一および二フッ化ベンゾチエピン化合物
BR0214924A (pt) * 2001-12-12 2004-11-30 Pharmacia Corp Métodos para tratamento de distúrbios oftálmicos com antagonistas de receptor de aldosterona de epóxi esteroidal
JP2005521653A (ja) 2002-01-17 2005-07-21 ファルマシア コーポレイション 先端ナトリウム同時依存性胆汁酸輸送（ａｓｂｔ）およびタウロコール酸塩取込みの阻害剤としての新規アルキル／アリールヒドロキシまたはケトチエピン化合物
MXPA04009033A (es) * 2002-03-18 2005-01-25 Pharmacia Corp Combinacion de un antagonista de receptor de aldosterona y acido nicotinico o un derivado de acido nicotinico.
CA2479259A1 (en) * 2002-03-18 2003-10-02 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
MXPA04009037A (es) * 2002-03-20 2005-01-25 Pharmacia Corp Formulacion de eplerenona de almacenamiento estable.
KR20040097201A (ko) * 2002-03-22 2004-11-17 파마시아 앤드 업존 캄파니 에플레레논의 제조 방법
US7235655B2 (en) * 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
US20070066579A1 (en) * 2002-08-16 2007-03-22 White Michael J 5-androsten-3beta-ol steroid intermediates and processs for their preparation
TW200406419A (en) * 2002-08-16 2004-05-01 Upjohn Co 5-Androsten-3 β- ol steroid intermediates and processes for their preparation
CN1694897A (zh) * 2002-11-06 2005-11-09 法玛西亚普强责任有限公司 7－羧基取代的甾族化合物的制备方法
KR100667123B1 (ko) * 2002-11-07 2007-01-12 파마시아 앤드 업존 캄파니 엘엘씨 Ｃ-7 치환된 5-안드로스텐의 제조 방법
CL2004000544A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
CL2004000574A1 (es) * 2003-03-21 2005-02-11 Pharmacia Corp Sa Organizada B Proceso para preparar un compuesto 17-espirolactona o la sal de lactona abierta por carbonilacion del correspondiente 17-alquenil o alquinil derivado, los intermediarios que se usan y su proceso de obtencion.
US20040266743A1 (en) * 2003-05-09 2004-12-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US20040265948A1 (en) * 2003-06-27 2004-12-30 White Michael Jon Microbial method for hydrolysis and oxidation of androst-5-ene and pregn-5-ene steroid esters
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
CA2560389A1 (en) * 2004-03-22 2005-10-06 Pharmacia & Upjohn Company Llc Improved process for the preparation of 9,11 epoxy steroids
US20070196471A1 (en) * 2004-04-02 2007-08-23 Thosar Shilpa S Micronized Eplerenone Compositions
US20050232957A1 (en) * 2004-04-14 2005-10-20 Katz Kenneth A Compositions and methods for moisturizing skin
CN1321128C (zh) * 2005-07-15 2007-06-13 浙江医药股份有限公司新昌制药厂 孕甾－4－烯－7，21－二甲酸，9，11－环氧－17－羟基－3－氧代，γ－内酯，甲酯，(7α,11α,17α)－的制备方法
WO2007025780A2 (en) * 2005-09-02 2007-03-08 Recordati Ireland Limited Aldosterone receptor antagonists
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
US20070248665A1 (en) * 2006-04-24 2007-10-25 Sherman Bernard C Compositions comprising co-precipitate of eplerenone and a water-soluble excipient
DE102006028032A1 (de) * 2006-06-14 2007-12-20 Henkel Kgaa Aufhell- und/oder Färbemittel mit Nitrilen
JP2010513325A (ja) * 2006-12-21 2010-04-30 アルファファーム ピーティーワイ リミテッド 医薬組成物
CA2582496A1 (en) * 2007-03-20 2008-09-20 Apotex Pharmachem Inc. Improved process for the preparation and purification of eplerenone
FR2917975B1 (fr) 2007-06-26 2009-10-16 Ceva Sante Animale Sa Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains
DE102008026793A1 (de) * 2008-06-02 2009-12-03 Bayer Schering Pharma Aktiengesellschaft C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
CN101863951B (zh) * 2009-04-15 2012-06-06 浙江省天台县奥锐特药业有限公司 依普利酮的制备方法
ES2523734T3 (es) 2009-05-28 2014-12-01 Novartis Ag Derivados aminopropiónicos sustituidos como inhibidores de neprilisina
EP3048100A1 (en) 2009-05-28 2016-07-27 Novartis AG Substituted aminobutyric derivatives as neprilysin inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
BR112012019725A2 (pt) * 2010-02-08 2020-11-10 Tao Tom Du usos de uma composição farmacêutica e uso de pelo menos um progestogênio
ES2566934T3 (es) 2010-05-10 2016-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina
EP2582365B1 (en) 2010-06-16 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for stimulating reepithelialisation during wound healing
TR201007653A2 (tr) 2010-09-20 2012-04-24 Bi̇lgi̇ç Mahmut Eplerenon içeren farmasötik kompozisyon
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
WO2012107513A1 (en) * 2011-02-10 2012-08-16 Crystal Pharma, S.A.U. Process for obtaining drospirenone
ITMI20121037A1 (it) * 2012-06-14 2013-12-15 Ind Chimica Srl Processo per la preparazione di nitrili utili come intermedi per la sintesi di molecole ad attivita' farmacologica
CN105073762B (zh) 2013-02-14 2017-03-08 诺华股份有限公司 作为nep(中性内肽酶)抑制剂的取代的联苯丁酰膦酸衍生物
CN104262450A (zh) * 2014-09-19 2015-01-07 江苏嘉逸医药有限公司 依普利酮的制备及精制方法
EP3009443B1 (en) 2014-10-17 2018-09-12 INDUSTRIALE CHIMICA S.r.l. Process for the preparation of 7alfa-(methoxycarbonyl)-3-oxo-17alfa-pregn-4,9(11)-dien-21,17-carbolactone, a useful intermediate for the synthesis of molecules with pharmacological activity
WO2017055248A1 (en) 2015-09-28 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of heart failure
WO2017064121A1 (en) 2015-10-13 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
CN105753930A (zh) * 2016-03-30 2016-07-13 北京万全德众医药生物技术有限公司 依普利酮的一种合成方法
ES2973248T3 (es) 2016-07-26 2024-06-19 Inst Nat Sante Rech Med Antagonista del receptor mineralocorticoide para el tratamiento de la osteoartritis
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
US20240366632A1 (en) 2021-08-31 2024-11-07 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of ocular rosacea

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3095412A (en) * 1961-12-19 1963-06-25 Searle & Co 9alpha, 11alpha-epoxy and 11beta-chloro-9alpha-hydroxy 17alpha-(2-carboxyethyl)-17beta-hydroxyandrost-4-en-3-one gamma-lactones and delta1 and delta6 analogs
GB1041534A (en) * 1963-04-24 1966-09-07 Merck & Co Inc 20-spiroxane compounds
US3729491A (en) * 1970-06-15 1973-04-24 Searle & Co 3,5-dioxo-a-nor-b-homo steroidal spirolactones
GB1368006A (en) * 1972-08-24 1974-09-25 Searle & Co 4alpha,7alpha-carbonyl-5-cyano-17-hzydroxy-3-oxo-5beta,17alpha- pregnane-21-carboxylic acid ypsilon-lactone
US3849404A (en) * 1973-03-09 1974-11-19 Searle & Co Purification of 6,7-dihydro-17-hydroxy-3-oxo-3'h-cyclopropa(6,7)-17alpha-pregna-4,6-diene-21-carboxylic acid gamma-lactones
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE2922500A1 (de) * 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
DE3111951A1 (de) * 1981-03-23 1982-09-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen 7(alpha)-alkoxycarbonyl-15ss-methylen-4-androstene, verfahren zu ihrer herstellung und verwendung als arzneimittel

Also Published As

Publication number Publication date
CA1220781A (en) 1987-04-21
ES8602846A1 (es) 1985-12-01
DK189484D0 (da) 1984-04-12
IE840906L (en) 1984-10-13
LU91072I2 (fr) 2004-04-07
AR241918A1 (es) 1993-01-29
ES531517A0 (es) 1985-12-01
DE122004000012I1 (de) 2012-05-16
PT78413A (en) 1984-05-01
AU2685384A (en) 1984-10-18
US4559332A (en) 1985-12-17
DE122004000012I2 (de) 2006-06-08
FI841400A0 (fi) 1984-04-09
IL71504A (en) 1987-07-31
NL300144I2 (nl) 2004-06-01
HU191406B (en) 1987-02-27
GR81834B (es) 1984-12-12
ATE39256T1 (de) 1988-12-15
ES8705460A1 (es) 1987-05-01
IL71504A0 (en) 1984-07-31
NO841465L (no) 1984-10-15
FI77669B (fi) 1988-12-30
ES544768A0 (es) 1987-05-01
ES544769A0 (es) 1987-05-01
ZA842710B (en) 1984-11-28
PH19997A (en) 1986-08-28
DK189484A (da) 1984-10-14
NL300144I1 (nl) 2004-06-01
AU565017B2 (en) 1987-09-03
DK163988B (da) 1992-04-27
DD251144A5 (de) 1987-11-04
AR242223A1 (es) 1993-03-31
NO159800C (no) 1989-02-08
EP0122232A1 (de) 1984-10-17
EP0122232B1 (de) 1988-12-14
AR242222A1 (es) 1993-03-31
FI77669C (fi) 1989-04-10
JPS59231100A (ja) 1984-12-25
NO159800B (no) 1988-10-31
PT78413B (en) 1986-08-22
IE57541B1 (en) 1992-10-07
ES8705461A1 (es) 1987-05-01
FI841400L (fi) 1984-10-14
DK163988C (da) 1992-09-21
DE3475622D1 (en) 1989-01-19
DD233375A5 (de) 1986-02-26
AR242221A1 (es) 1993-03-31
NZ207826A (en) 1986-07-11
JPH0212479B2 (es) 1990-03-20
ES544770A0 (es) 1987-05-01

Similar Documents

Publication Publication Date Title
ES8705459A1 (es) Procedimiento para la obtencion de nuevos compuestos este- roides
AR245718A1 (es) Procedimiento para preparar un compuesto de imidazo (4,5-b)-piridina
AR241226A1 (es) 3-(2,2-difluorbenzodioxol-4-il)-4-cianopirrol procedimiento para su preparacion, intermediario y composion microbicida que contiene dicho compuesto.
ES483767A1 (es) Procedimiento para producir n-arilsulfonil-l-argininamidas
MX168442B (es) Procedimiento para la preparacion de 2-oxo-1,3-dioxolanos
ES8507480A1 (es) Un metodo para producir un derivado de amina
ES8301980A1 (es) Procedimiento para la preparacion de 8-arilalcohil-3-fenil-3-nortropanoles .
Majeski et al. Controlled potential oxidation of anthracene in acetonitrile. II
MX3300E (es) Procedimiento para la obtencion de una composicion insecticida que contiene como compuestos activos (+)-cis, trans crisantematos
ES444478A1 (es) Mejoras introducidas en un procedimiento para eliminar el oxigeno disuelto en el agua.
ES8405000A1 (es) Un procedimiento para la preparacion de un derivado de carbostirilo.
ES8609323A1 (es) Un procedimiento para la preparacion de hexahidro-arilquinolizinas sustituidas.
ES448509A1 (es) Mejoras en el procedimiento de preparacion de derivados fluordeshidroxilados de alcoholes organicos.
ES8601089A1 (es) Procedimiento para la preparacion de compuestos antipsoria- ticos naftalenicos
KR840006766A (ko) 항 진균제의 제조방법
ES8204723A1 (es) Un procedimiento para la preparacion de 4-alcohilo inferior-3-fenoxipiridina-1-oxido
KR830006328A (ko) 신규 선택적 용매화 분해방법
SE7608379L (sv) Forfarande for framstellning av veteperoxid
SE7713129L (sv) Sett att framstella fenylalkylkarboxylsyror
GB1082574A (en) Steroid esters
ES8202826A1 (es) Procedimiento para la produccion de una 5,10-dihidroimidazo (2,1-b) quinazolina
ES8801636A1 (es) Un procedimiento para preparar nuevos derivados de imidazol
SE7604245L (sv) Nya fungicida blandningar
ES8204992A1 (es) Procedimiento para la obtencion de compuestos poliazahetero-ciclicos
ATE9871T1 (de) Amoxicillinsolvat, verfahren zur herstellung und verfahren zur herstellung von dieses solvat enthaltenden injizierbaren praeparaten.

Legal Events

Date Code Title Description
PC1A Transfer granted
FD1A Patent lapsed

Effective date: 20070120